UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 134

Sortiert nach

Variables with time-varying effects and the Cox model: some statistical concepts illustrated with a prognostic factor study in breast cancer

BMC medical research methodology, 2010-03, Vol.10 (1), p.20-20, Article 20

2010

Volltextzugriff (PDF)

Functional Decline in Older Patients With Cancer Receiving First-Line Chemotherapy

Journal of clinical oncology, 2013-11, Vol.31 (31), p.3877-3882

2013

Volltextzugriff (PDF)

Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study

Clinical cancer research, 2019-08, Vol.25 (15), p.4611-4615

2019

Volltextzugriff (PDF)

Hierarchical Changepoint Models for Biochemical Markers Illustrated by Tracking Postradiotherapy Prostate-Specific Antigen Series in Men With Prostate Cancer

Annals of epidemiology, 2008-04, Vol.18 (4), p.270-282

2008

Volltextzugriff (PDF)

A Statistical Evaluation of Rules for Biochemical Failure After Radiotherapy in Men Treated for Prostate Cancer

International journal of radiation oncology, biology, physics, 2009-12, Vol.75 (5), p.1357-1363

2009

Volltextzugriff (PDF)

Correction: Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study

Clinical cancer research, 2019-08, Vol.25 (15), p.4859-4859

2019

Volltextzugriff (PDF)

REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors—Results of the non-MSI-H metastatic colorectal cancer (mCRC) cohort

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.4019-4019

2020

Volltextzugriff (PDF)

Detection of frailty in elderly cancer patients: Improvement of the G8 screening test

Journal of geriatric oncology, 2016-03, Vol.7 (2), p.99-107

2016

Volltextzugriff (PDF)

Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: Formal consensus method for the development of guidelines for standardised time-to-event endpoints’ definitions in cancer clinical trials

European journal of cancer (1990), 2013-03, Vol.49 (4), p.769-781

2013

Volltextzugriff (PDF)

A method is presented to plan the required sample size when estimating regression-based reference limits

Journal of clinical epidemiology, 2007-06, Vol.60 (6), p.610-615

2007

Volltextzugriff (PDF)

Detecting Trends in Noisy Data Series: Application to Biomarker Series

American journal of epidemiology, 2008-05, Vol.167 (9), p.1130-1139

2008

Volltextzugriff (PDF)

A charting tool for estimating the PSA doubling time in patients with prostate cancer

International journal of radiation oncology, biology, physics, 2006-09, Vol.66 (1), p.315-316

2006

Volltextzugriff (PDF)

Tumor fraction to improve patient selection for oncology early phase clinical trials: Analysis of two precision medicine studies

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3005-3005

2023

Volltextzugriff (PDF)

Handling missing covariates in observational studies: An illustration with the assessment of prognostic factors of survival outcomes in sarcoma in irradiated fields (SIF)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.11558-11558

2022

Volltextzugriff (PDF)

Preliminary results of a phase IB study of olaparib with concomitant radiotherapy in locally advanced/unresectable soft-tissue sarcoma from the French Sarcoma Group

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.11522-11522

2022

Volltextzugriff (PDF)

Diagnostic performance of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) for the evaluation of hypermetabolic lymphadenopathy mediastinum lower, posterior, and middle, detected by PET-CT with 18F-FDG (PET) (APOGEE Study)

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.798-798

2020

Volltextzugriff (PDF)

CAIRE: A basket multicenter open-label phase 2 study evaluating the EZH2 inhibitor tazemetostat in combination with durvalumab in patients with advanced solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS2703-TPS2703

2022

Volltextzugriff (PDF)

Metzolimos metronomic cyclophosphamide (CP) and methotrexate (MTX) combined with zoledronic acid (ZA) and sirolimus (SIR) in patients with advanced solid tumor with bone metastasis and advanced pretreated osteosarcoma (OSS): A phase Ib study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.11526-11526

2022

Volltextzugriff (PDF)

A decision curve analysis of the clinical usefulness of a two-step frailty assessment strategy in older patients with prostate, breast, colorectal, or lung cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.12011-12011

2022

Volltextzugriff (PDF)

REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors—Results of the oesophageal or gastric carcinoma (OGC) cohort

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4060-4060

2022

Volltextzugriff (PDF)

REGOMUNE: Phase II study of regorafenib plus avelumab in solid tumors—Results of the gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) cohort

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4125-4125

2022

Volltextzugriff (PDF)

A phase I/II study of regorafenib (R) plus avelumab (A) in digestive tumors

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS3125-TPS3125

2018

Volltextzugriff (PDF)

PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: A multicenter phase II trial

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.11507-11507

2021

Volltextzugriff (PDF)

Regomune: A phase II study of regorafenib + avelumab in solid tumors—Results of the biliary tract cancer (BTC) cohort

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4096-4096

2021

Volltextzugriff (PDF)

Benefit of intensified perioperative chemotherapy within high-risk CINSARC patients with resectable soft tissue sarcomas (CIRSARC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS11078-TPS11078

2019

Volltextzugriff (PDF)

1 – 25 von 134

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(128)
Mit Volltextzugriff
(130)

Publikationsform

Artikel
(132)
Dissertationen
(2)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Variables with time-varying effects and the Cox model: some statistical concepts illustrated with a prognostic factor study in breast cancer

Functional Decline in Older Patients With Cancer Receiving First-Line Chemotherapy

Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study

Hierarchical Changepoint Models for Biochemical Markers Illustrated by Tracking Postradiotherapy Prostate-Specific Antigen Series in Men With Prostate Cancer

A Statistical Evaluation of Rules for Biochemical Failure After Radiotherapy in Men Treated for Prostate Cancer

Correction: Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study

REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors—Results of the non-MSI-H metastatic colorectal cancer (mCRC) cohort

Detection of frailty in elderly cancer patients: Improvement of the G8 screening test

Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: Formal consensus method for the development of guidelines for standardised time-to-event endpoints’ definitions in cancer clinical trials

A method is presented to plan the required sample size when estimating regression-based reference limits

Detecting Trends in Noisy Data Series: Application to Biomarker Series

A charting tool for estimating the PSA doubling time in patients with prostate cancer

Tumor fraction to improve patient selection for oncology early phase clinical trials: Analysis of two precision medicine studies

Handling missing covariates in observational studies: An illustration with the assessment of prognostic factors of survival outcomes in sarcoma in irradiated fields (SIF)

Preliminary results of a phase IB study of olaparib with concomitant radiotherapy in locally advanced/unresectable soft-tissue sarcoma from the French Sarcoma Group

Diagnostic performance of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) for the evaluation of hypermetabolic lymphadenopathy mediastinum lower, posterior, and middle, detected by PET-CT with 18F-FDG (PET) (APOGEE Study)

CAIRE: A basket multicenter open-label phase 2 study evaluating the EZH2 inhibitor tazemetostat in combination with durvalumab in patients with advanced solid tumors

Metzolimos metronomic cyclophosphamide (CP) and methotrexate (MTX) combined with zoledronic acid (ZA) and sirolimus (SIR) in patients with advanced solid tumor with bone metastasis and advanced pretreated osteosarcoma (OSS): A phase Ib study

A decision curve analysis of the clinical usefulness of a two-step frailty assessment strategy in older patients with prostate, breast, colorectal, or lung cancer

REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors—Results of the oesophageal or gastric carcinoma (OGC) cohort

REGOMUNE: Phase II study of regorafenib plus avelumab in solid tumors—Results of the gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) cohort

A phase I/II study of regorafenib (R) plus avelumab (A) in digestive tumors

PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: A multicenter phase II trial

Regomune: A phase II study of regorafenib + avelumab in solid tumors—Results of the biliary tract cancer (BTC) cohort

Benefit of intensified perioperative chemotherapy within high-risk CINSARC patients with resectable soft tissue sarcomas (CIRSARC)

Suchergebnisse filtern